NR 293 Week 6 Assignment: RUA: Medication Teaching Plan – Nurtec (ODT) | GRADED A

Nurtec ODT (Rimegepant) Chamberlain College of Nursing NR 293 – Pharmacology Rimegepant (Nurtec ODT) is a medication that was first approved by the FDA on February 27, 2020, to be used as a t reatment for acute migraines (National Center for Biotechnology Information, 2020). Rimegepant is a calcitonin gene-related peptide receptor antagonist (CGRP), which is also referred to as gepants. Nurtec is the first CGRP to come in an orally disintegrating tablet but has drug interactions with CYP3A4 inhibitors, CYP3A inducers, and transporters. Rimegepant offers migraine relief to an expanded population when compared to triptans. Triptans constrict the blood vessels, which leaves a possibility for coronary artery construction as well. Since Nurtec does not have these properties, patients with hypertension or other heart-related problems are not contraindicated in this medication (Lipton, et al., 2020). Nurtec should be avoided in pregnant, breastfeeding patie Show Less